

# Frauke MÃ¼cksch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2457967/publications.pdf>

Version: 2024-02-01

33  
papers

11,933  
citations

236925

25  
h-index

395702

33  
g-index

62  
all docs

62  
docs citations

62  
times ranked

17851  
citing authors

#	ARTICLE	IF	CITATIONS
1	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , 2020, 584, 437-442.	27.8	1,742
2	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021, 591, 639-644.	27.8	1,355
3	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. <i>ELife</i> , 2020, 9, .	6.0	1,239
4	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021, 592, 616-622.	27.8	1,232
5	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , 2020, 182, 828-842.e16.	28.9	724
6	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. <i>New England Journal of Medicine</i> , 2021, 384, 2212-2218.	27.0	647
7	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , 2021, 595, 426-431.	27.8	610
8	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	503
9	Enhanced SARS-CoV-2 neutralization by dimeric IgA. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	379
10	Plasma Neutralization of the SARS-CoV-2 Omicron Variant. <i>New England Journal of Medicine</i> , 2022, 386, 599-601.	27.0	371
11	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , 2021, 12, 4196.	12.8	332
12	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	283
13	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , 2021, 600, 517-522.	27.8	239
14	Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. <i>Journal of Infectious Diseases</i> , 2021, 223, 389-398.	4.0	233
15	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , 2021, 54, 1853-1868.e7.	14.3	230
16	Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. <i>Nature</i> , 2022, 607, 128-134.	27.8	197
17	Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	3.9	154
18	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. <i>Nature</i> , 2021, 595, 278-282.	27.8	154

#	ARTICLE	IF	CITATIONS
19	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. <i>Nature</i> , 2021, 593, 424-428.	27.8	108
20	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. <i>Immunity</i> , 2022, 55, 998-1012.e8.	14.3	86
21	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. <i>Cell Reports</i> , 2021, 36, 109760.	6.4	80
22	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. <i>Cell</i> , 2021, 184, 3205-3221.e24.	28.9	73
23	Maturation of the matrix and viral membrane of HIV-1. <i>Science</i> , 2021, 373, 700-704.	12.6	60
24	Quantification of phosphoinositides reveals strong enrichment of PIP2 in HIV-1 compared to producer cell membranes. <i>Scientific Reports</i> , 2019, 9, 17661.	3.3	45
25	Synchronized HIV assembly by tunable PIP2 changes reveals PIP2 requirement for stable Gag anchoring. <i>ELife</i> , 2017, 6, .	6.0	45
26	Coagulation factors directly cleave SARS-CoV-2 spike and enhance viral entry. <i>ELife</i> , 2022, 11, .	6.0	34
27	HIV-1 matrix-tRNA complex structure reveals basis for host control of Gag localization. <i>Cell Host and Microbe</i> , 2021, 29, 1421-1436.e7.	11.0	22
28	Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis. <i>Lancet Microbe</i> , The, 2022, 3, e493-e502.	7.3	22
29	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009688.	4.7	16
30	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COV2.S vaccine in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	10
31	Neutralizing activity to SARS-CoV-2 of convalescent and control plasma used in a randomized controlled trial. <i>Transfusion</i> , 2021, 61, 1363-1369.	1.6	8
32	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. <i>Journal of Experimental Medicine</i> , 2022, 219, .	8.5	6
33	Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100028.	1.0	2